% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{AfsharOromieh:124429,
      author       = {A. Afshar-Oromieh and T. Holland-Letz$^*$ and F. L. Giesel
                      and C. Kratochwil and W. Mier and S. Haufe and N. Debus and
                      M. Eder$^*$ and M. Eisenhut$^*$ and M. Schäfer$^*$ and O.
                      Neels$^*$ and M. Hohenfellner and K. Kopka$^*$ and H.-U.
                      Kauczor and J. Debus and U. Haberkorn$^*$},
      title        = {{D}iagnostic performance of (68){G}a-{PSMA}-11
                      ({HBED}-{CC}) {PET}/{CT} in patients with recurrent prostate
                      cancer: evaluation in 1007 patients.},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {44},
      number       = {8},
      issn         = {1619-7089},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {DKFZ-2017-01306},
      pages        = {1258 - 1268},
      year         = {2017},
      abstract     = {Since the clinical introduction of (68)Ga-PSMA-11 PET/CT,
                      this imaging method has rapidly spread and is now regarded
                      as a significant step forward in the diagnosis of recurrent
                      prostate cancer (PCa). The aim of this study was to analyse
                      the influence of several variables with possible influence
                      on PSMA ligand uptake in a large cohort.We performed a
                      retrospective analysis of 1007 consecutive patients who were
                      scanned with (68)Ga-PSMA-11 PET/CT (1 h after injection)
                      from January 2014 to January 2017 to detect recurrent
                      disease. Patients with untreated primary PCa or patients
                      referred for PSMA radioligand therapy were excluded. The
                      possible effects of different variables including PSA level
                      and PSA doubling time (PSADT), PSA velocity (PSAVel),
                      Gleason score (GSC, including separate analysis of GSC 7a
                      and 7b), ongoing androgen deprivation therapy (ADT), patient
                      age and amount of injected activity were evaluated.In
                      $79.5\%$ of patients at least one lesion with
                      characteristics suggestive of recurrent PCa was detected. A
                      pathological (positive) PET/CT scan was associated with PSA
                      level and ADT. GSC, amount of injected activity, patient
                      age, PSADT and PSAVel were not associated with a positive
                      PET/CT scan in multivariate analysis.(68)Ga-PSMA-11 PET/CT
                      detects tumour lesions in a high percentage of patients with
                      recurrent PCa. Tumour detection is clearly associated with
                      PSA level and ADT. Only a tendency for an association
                      without statistical significance was found between higher
                      GSC and a higher probability of a pathological PET/CT scan.
                      No associations were found between a pathological
                      (68)Ga-PSMA-11 PET/CT scan and patient age, amount of
                      injected activity, PSADT or PSAVel.},
      cin          = {E060 / C060 / E030},
      ddc          = {610},
      cid          = {I:(DE-He78)E060-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)E030-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28497198},
      doi          = {10.1007/s00259-017-3711-7},
      url          = {https://inrepo02.dkfz.de/record/124429},
}